NASDAQ: IPSCCentury Therapeutics Inc Stock
$2.98+0.14 (+4.93%)
Updated Apr 18, 2024
IPSC Price
$2.98
Fair Value Price
$0.03
Market Cap
$192.83M
52 Week Low
$1.28
52 Week High
$5.51
P/E
-1.29x
P/B
1.04x
P/S
88.11x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.24M
Earnings
-$136.67M
Gross Margin
100%
Operating Margin
-6,006.8%
Profit Margin
-6,115.1%
Debt to Equity
0.95
Operating Cash Flow
-$88M
Beta
1.19
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
IPSC Overview
Century Therapeutics Incorporated is a biotech company developing transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also advancing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma. Century Therapeutics was founded in 2018 and is headquartered in Philadelphia, PA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IPSC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IPSC ($2.98) is overvalued by 8,478.85% relative to our estimate of its Fair Value price of $0.03 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IPSC ($2.98) is not significantly undervalued (8,478.85%) relative to our estimate of its Fair Value price of $0.03 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IPSC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IPSC due diligence checks available for Premium users.
Be the first to know about important IPSC news, forecast changes, insider trades & much more!
IPSC News
Valuation
IPSC fair value
Fair Value of IPSC stock based on Discounted Cash Flow (DCF)
Price
$2.98
Fair Value
$0.03
Overvalued by
8,493.27%
IPSC ($2.98) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IPSC ($2.98) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IPSC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IPSC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.29x
Industry
15.68x
Market
41.33x
IPSC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.04x
Industry
5.76x
IPSC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IPSC's financial health
Profit margin
Revenue
$268.0k
Net Income
-$39.4M
Profit Margin
-14,700.7%
IPSC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IPSC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$360.7M
Liabilities
$175.9M
Debt to equity
0.95
IPSC's short-term assets ($176.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IPSC's short-term assets ($176.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IPSC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$26.2M
Investing
$18.6M
Financing
-$356.0k
IPSC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IPSC vs Biotech Stocks
Century Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.